المؤلفون: Jackson TL; School of Medicine, King's College London, London, United Kingdom., Boyer D; Retina-Vitreous Associates Medical Group, Beverly Hills, California., Brown DM; Blanton Eye Institute, Houston Methodist Hospital, Retina Consultants of Houston, Houston, Texas., Chaudhry N; New England Retina Associates, Guilford, Connecticut., Elman M; Elman Retina Group, Baltimore, Maryland., Liang C; Tyrogenex Inc, Rockville, Maryland., O'Shaughnessy D; Tyrogenex Inc, Rockville, Maryland., Parsons EC; Tyrogenex Inc, Rockville, Maryland., Patel S; Retina Research Institute of Texas, Abilene., Slakter JS; Digital Angiography Reading Center, New York, New York., Rosenfeld PJ; Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, Florida.

المصدر: JAMA ophthalmology [JAMA Ophthalmol] 2017 Jul 01; Vol. 135 (7), pp. 761-767.

نوع المنشور: Clinical Trial, Phase I; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: American Medical Association Country of Publication: United States NLM ID: 101589539 Publication Model: Print Cited Medium: Internet ISSN: 2168-6173 (Electronic) Linking ISSN: 21686165 NLM ISO Abbreviation: JAMA Ophthalmol Subsets: MEDLINE

مواضيع طبية MeSH: Visual Acuity*, Enzyme Inhibitors/*administration & dosage , Macular Degeneration/*drug therapy , Protein-Tyrosine Kinases/*antagonists & inhibitors, Administration, Oral ; Aged ; Dose-Response Relationship, Drug ; Female ; Fluorescein Angiography ; Follow-Up Studies ; Fundus Oculi ; Humans ; Macular Degeneration/diagnosis ; Macular Degeneration/physiopathology ; Male ; Middle Aged ; Retrospective Studies ; Time Factors ; Tomography, Optical Coherence ; Treatment Outcome